HARP News and Press, Harpoon Therapeutics Inc. From 08/21/20

Gainers:  Hancock Jaffe Laboratories (NASDAQ: HJLI ) +127% . More news on: Hancock Jaffe Laboratories, Inc., Harpoon Therapeutics, Inc., ShiftPixy, Inc., Stocks on the move, , Read more ...

Harpoon Therapeutics (NASDAQ: HARP ) : Q2 GAAP EPS of -$0.51 misses by $0.01 . More news on: Harpoon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Presented positive interim Phase 1 clinical trial data for PSMA-targeting HPN424 in prostate cancer at ASCO20, supporting increased dose escalation Dosed first patient with HPN217 targeting BCMA for the treatment of multiple myeloma, triggering a $50 million milestone payment from A...

Joanne Viney, Ph.D., brings expertise as an immunologist and veteran biotech executive to the board Drs. Luke Evnin and Patrick Baeuerle step down from the Harpoon board Dr. Baeuerle remains as a scientific advisor to the company SOUTH SAN FRANCISCO, Calif., July 02, 2020 (GLO...

SOUTH SAN FRANCISCO, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced new information regarding its participation in two upcoming investor virtual conferen...

SOUTH SAN FRANCISCO, Calif., June 11, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate i...

Gainers: Cemtrex (NASDAQ: CETX )  +209% . More news on: Cemtrex, Inc., Digital Ally, Inc., Allied Esports Entertainment Inc., Stocks on the move, , Read more ...

The following slide deck was published by Harpoon Therapeutics, Inc. in conjunction with this Read more ...

The on-going dose escalation Phase 1 study has enrolled 44 patients with progressive, metastatic castration-resistant prostate cancer in 11 cohorts.   Initial safety data showed that HPN424 is generally well-tolerated, and cytokine-related adverse events have been transient and manag...

SOUTH SAN FRANCISCO, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that interim Phase 1 data for HPN424 for prostate cancer will be presented at the Amer...